Neurocrine Biosciences NBIX Return on invested capital
Return on invested capital at other companies
Other financials
Where this comes from
Calculated from Neurocrine Biosciences’s reported figures.
Based on trailing twelve months.
The official record: Neurocrine Biosciences’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Neurocrine Biosciences's return on invested capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Neurocrine Biosciences's return on invested capital?
- Neurocrine Biosciences (NBIX) reported return on invested capital of 17.5% in Q1 2026.
- How has Neurocrine Biosciences's return on invested capital changed year-over-year?
- Neurocrine Biosciences's return on invested capital increased by 40.9% year-over-year, from 12.4% to 17.5%.
- What is the long-term trend for Neurocrine Biosciences's return on invested capital?
- Over 2 years (2023 to 2025), Neurocrine Biosciences's return on invested capital has grown at a 28.8% compound annual growth rate (CAGR), from 31% to 51.5%.
- What does return on invested capital mean?
- The after-tax return the business earns on all the capital — debt and equity — invested in it.
- How do you interpret return on invested capital?
- The cleanest measure of business quality: ROIC sustained above the cost of capital creates value, below it destroys value. Compare against WACC, not against zero.
- How does return on invested capital compare across companies?
- Highly comparable across companies as a quality screen. Sector-sensitive definitions of invested capital mean banks/insurers are best excluded.